Benefitting from a Swiss banking renaissance

(Full access for Members only)

Benefitting from a Swiss banking renaissance

13 July 2022

What readers said about this report

Eight years after the end of Swiss banking secrecy, private banking "Made in Switzerland" is set for a new boom.

The stock featured in this research report is one of the best-known brand names in this sector. In fact, quite a few of you will already be a client!

However, few people will realise that it currently offers the best buying opportunity since the Great Financial Crisis.

At no point since 2008 has this particular stock been so attractive:

  • Record-low valuation in absolute terms.
  • The prospect of a new multi-year boom for its business.
  • While you wait, a >6% p.a. dividend yield and massive share buy-backs.

This research report entails:

  • An analysis of why "tax havens" the world over will become the target of unprecedented political repercussions (one of the great underreported stories of today's financial markets – but bound to hit the headlines soon).
  • An explanation as to how the featured company is ideally positioned to benefit from these developments.
  • An overview of all key figures and estimates for investing in its stock.

If you are looking to prepare yourself for the new age of geopolitical instability, this stock should be on your radar.

Not a Member yet? Sign up for a Membership - just USD 49/year.
Already a Member? Log into your account to download the report.

|  What readers said about this report

Ákos V.
February 2024

A nice hit again, thanks for the idea.

l  Report updates

Not a Member yet? Sign up for a Membership.
Already a Member? Log into your account to download the report updates.

26 July 2022

Report Update (PDF - 0.7MB)

Most recent

Sark – it’s not a big deal

Sark – it’s not a big deal

I had mobilised GBP 30m to buy a portfolio of real estate in Sark, with plans to IPO the company. How did it go, and what may happen next?

read more

Latest reports (for Members only)

2-2.5x from an investment holding liquidation

2-2.5x from an investment holding liquidation

This AIM-listed small-cap will likely return all its capital to shareholders. Underresearched by investors, it's an opportunity that shouldn't even exist – but it does.

Ukraine reconstruction: one stock to benefit

Ukraine reconstruction: one stock to benefit

If or when the war in Ukraine ends, this stock will likely become the focus of investor money pushing into the country.

Actinium-225, aka "the world's rarest drug"

Actinium-225, aka "the world's rarest drug"

This little-known Western European company could become the global market leader for supplying the uber-rare "Ac-225", a potent weapon to treat cancer.